Development of proprietary medicines
We look for new medicines in oncology and neuropsychiatry
The development of proprietary medicines at Adamed is focused on two therapeutic areas: oncology and neuropsychiatry. Thanks to our multidisciplinary team of experts and advanced technological facilities,we have the capacity to execute highly complex projects, such as the development of new molecules.
Our laboratories provide an agile combination of technologies to select and test drug candidates and transfer them to the clinical development stage. We possess the necessary knowledge in synthesis and analysis of chemical compounds and biological molecules, biochemistry and biophysics, cell biology, tissue biology, pharmacokinetics, pharmacodynamics, toxicology, and physiology. In our research projects we use advanced mathematical, analytical, and in silico modelling tools.
We are currently running multiple ongoing projects conducted as part of four large research programmes and three drug candidate molecules. The first one is a selective inhibitor MDM2, which exhibits cancer-fighting activity in sarcomas, lymphomas, and leukemias. The second one is a double-specific ligand targeting serotonin receptors 5-HT6 and 5-HT2A. In the future, this molecule is expected to be used in the treatment of psychotic and cognitive disorders in patients with dementia. The third molecule is a recombinant fusion protein with pro-apoptotic and anti-angiogenic activity. It is a drug candidate for solid tumours of the gastrointestinal tract.
Innovation Department Labs & Teams
The Lab possesses infrastructure and software for the modelling, visualisation, and comparative analysis of spatial structures which are molecular binding sites for newly developed medicines, effector molecules, and their mutual interactions. The team also has expertise in high-throughput compound analysis and protein sequencing. The Lab also develops Adamed’s own research algorithms and database software for the collection, analysis, and processing of results obtained through experiments.
The Biotechnology Lab is responsible for developing protein production processes as part of Adamed’s innovative research programmes. The Lab’s tasks include optimisation of the following protein manufacturing stages: designing DNA constructs coding the target molecules, selection of bacterial strains and expression vectors, establishing the optimal conditions for expression, and scaling the manufacturing process.
Content: The main activities of the Proteomics Lab include the design and implementation of purification methods for recombinant proteins with therapeutic potential, analytics of proteins and bioconjugates, and providing their exact characteristics. An important part of the Lab’s work is participation in studies of molecular mechanisms of action and molecule pharmacology to prepare the molecules for advanced stages of the development process as drug candidates.
Content: Eukaryotic cell cultures are routinely used in biotechnological and toxicological protocols. Cells cultivated in appropriate conditions can be used for screening newly created molecules, thereby significantly reducing the number of animal tests. At the early stages of the drug development process, properly planned experiments using cell lines enable investigators to answer many questions about the mechanism of action, initial toxicological activity, or interactions with other substances.
The Laboratory Animals Team is responsible for conducting research studies to acquire the knowledge necessary for the development of drug candidates. The Team follows national and European guidelines and is committed to maintaining high ethical, hygienic, and methodological standards in the rodent vivarium. Ensuring the welfare of laboratory animals based on the 3R principle and close collaboration with the Research Department, the Preclinical Development Team, and external expert organisations allow the Team to accurately conduct studies in order to ensure highly reliable results.
The Preclinical Development Team coordinates the company’s activities in the area of preclinical studies of selected drug candidates. With its vast skills and experience, the Team can efficiently assess if molecules are ready for phase 1 clinical trials (known as first-in-human, FIH) and provide significant support for finished value-added dosage forms, allowing Adamed to obtain regulatory approval for bringing new medicines to the Polish and international markets.
Content: The CNS Team is responsible for all research activities carried out by the Innovation Department in the area of central nervous system disorders. The Team’s tasks include the selection of clinical indications and biological targets, designing new chemical molecules with therapeutic potential, and providing broad in vitro and in vivo pharmacological characteristics.
Institute of Biochemistry and Biophysics
Polish Academy of Sciences in Warsaw
Institute of Physical Chemistry
Polish Academy of Sciences in Warsaw
Institute of Immunology and Experimental Therapy
Polish Academy of Sciences in Wroclaw
Wroclaw Research Centre EiT+
of Molecular and Cell Biology
Institute of Industrial Organic Chemistry,
Branch Office in Pszczyna
Pharmaceutical Research Institute
Faculty of Pharmacy,
Jagiellonian University Collegium Medicum
The John Paul II Catholic University in Lublin
Institute of Pharmacology,
Polish Academy of Sciences in Krakow
Institute of Psychiatry and Neurology
Institute of Mother and Child
Haematology and Transfusion
The Maria Skłodowska-Curie
Institute Oncology Centre
Medical Centre of Postgraduate Education
Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University